Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Elsevier Science full text link Elsevier Science Free PMC article
Full text links

Actions

Share

Review
.2005 Jun;81(2):285-99.
doi: 10.1016/j.pbb.2005.01.026.

Self-administration of cannabinoids by experimental animals and human marijuana smokers

Affiliations
Review

Self-administration of cannabinoids by experimental animals and human marijuana smokers

Zuzana Justinova et al. Pharmacol Biochem Behav.2005 Jun.

Abstract

Drug self-administration behavior has been one of the most direct and productive approaches for studying the reinforcing effects of psychoactive drugs, which are critical in determining their abuse potential. Cannabinoids, which are usually abused by humans in the form of marijuana, have become the most frequently abused illicit class of drugs in the United States. The early elucidation of the structure and stereochemistry of delta-9-tetrahydrocannabinol (THC) in 1964, which is now recognized as the principal psychoactive ingredient in marijuana, activated cannabinoid research worldwide. This review examines advances in research on cannabinoid self-administration behavior by humans and laboratory animals. There have been numerous laboratory demonstrations of the reinforcing effects of cannabinoids in human subjects, but reliable self-administration of cannabinoids by laboratory animals has only recently been demonstrated. It has now been shown that strong and persistent self-administration behavior can be maintained in experimentally and drug-naïve squirrel monkeys by doses of THC comparable to those in marijuana smoke inhaled by humans. Furthermore, reinforcing effects of some synthetic CB1 cannabinoid agonists have been recently reported using intravenous and intracerebroventricular self-administration procedures in rats and mice. These findings support previous conclusions that THC has a pronounced abuse liability comparable to other drugs of abuse under certain experimental conditions. Self-administration of THC by squirrel monkeys provides the most reliable animal model for human marijuana abuse available to date. This animal model now makes it possible to study the relative abuse liability of other natural and synthetic cannabinoids and to preclinically assess new therapeutic strategies for the treatment or prevention of marijuana abuse in humans.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Average plasma levels (± SD) of Δ9-THC in two groups of marijuana smokers (heavy and light users) after intravenous administration of Δ9-THC (5 mg; panel A) and after smoking a marijuana cigarette (heavy: 12.7 ± 1.3 mg of THC smoked; light: 13.4 ± 1.6 mg of THC smoked; panel B). See Lindgren et al., 1981 for more detailed information on methods and plasma levels. Modified from Lindgren et al., 1981.
Figure 2
Figure 2
Schematic drawing of a squirrel monkey sitting in a self-administration chair. During daily one-hour sessions, monkeys sat inside the experimental chamber, restrained in the seated position by a waist lock on the Plexiglas chair. At the start of each session, a white-house light was turned off and a green stimulus light was turned on; ten lever presses turned off the green light and produced a 2-s amber light paired with i.v. injection of THC (0.2 ml in 0.2 s) delivered from a syringe pump outside the chamber. There was a 60-s time-out period after each injection, during which the chamber was dark and lever presses had no programmed consequences (a 10-response, fixed-ratio schedule of i.v. THC injection with a 60-s time-out; FR 10, TO 60 s).
Figure 3
Figure 3
THC dose-response curves in squirrel monkeys with no history of exposure to other drugs (n = 3) and in squirrel monkeys with a history of cocaine self-administration (n = 4). Numbers of injections per session (left panel), overall rates of responding in the presence of a green light signalling THC availability (middle panel) and total THC intake per session (right panel) are presented as a function of injection dose of THC. Each symbol represents the mean (± S.E.M.) of the last three sessions under each THC injection dose condition and under a vehicle condition from three or four monkeys, with the exception of the values for the 1 μg/kg/injection dose of THC, which represent mean results from two monkeys. *P < 0.05, **P < 0.01 post-hoc comparisons with the vehicle conditions after significant one-way ANOVA for repeated measures main effect, Dunnett’s test. Modified from Tanda et al., 2000 and Justinova et al., 2003.
Figure 4
Figure 4
A. Intravenous self-administration of WIN 55,212-2 by rats. Each bar represents the mean ± S.E.M number of injections per session during 6 consecutive sessions immediately after 3 days of stable responding (n = 12-14). Doses are expressed as μg/kg per injection. **P<0.01 and *P<0.05 significant difference from vehicle group. Modified from Fattore et al., 2001.B. Effects of acute priming injections of WIN 55,212-2, heroinor cocaine on reinstatement of cannabinoid-seeking behavior following prolonged abstinence. Each bar represents the mean ± S.E.M of active nose-pokes over the last 3 days of cannabinoid self-administration (training), over the last five consecutive sessions of extinction (EXT) and during reinstatement test sessions (priming). Doses are expressed as mg/kg (i.p.). *P<0.001 vs respective EXT;#P<0.05,##P<0.01 and###P<0.001 vs respectivetraining;§P<0.05 betweenprimings of the two doses of WIN 55,212-2. ANOVA followed bypost hoc test (n=7-8). Modified from Spano et al., 2004.
Figure 5
Figure 5
Effects of pretreatment with 0.03 and 0.1 mg/kg naltrexone on self-administration responding maintained by THC over consecutive sessions. Number of injections per session during THC (4 μg/kg/injection) self-administration sessions after pretreatment with vehicle (sessions 1-3 and 9-11) or naltrexone (sessions 4-8), and numbers of injections per session during self-administration sessions when saline was substituted for THC (sessions 4-8) are shown. Symbols represent the means (± S.E.M.) of injections per session from 4 monkeys. **P<0.01, post-hoc comparisons with the last THC session before naltrexone pretreatment or saline substitution (session 3) after significant one-way ANOVA for repeated measures main effect, Dunnett’s test. Modified from Justinova et al., 2004.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986;38:21–43. - PubMed
    1. Alici T, Appel JB. Increasing the selectivity of the discriminative stimulus effects of D9-tetrahydrocannabinol: complete substitution with methanandamide. Pharmacol Biochem Behav. 2004 In press: manuscript PBB-69517. - PubMed
    1. Arnold JC, Hunt GE, McGregor IS. Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats. Life Sci. 2001;70:97–108. - PubMed
    1. Arnold JM, Roberts DC. A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol Biochem Behav. 1997;57:441–447. - PubMed
    1. Ashton H, Golding J, Marsh VR, Millman JE, Thompson JW. The seed and the soil: effect of dosage, personality and starting state on the response to delta 9 tetrahydrocannabinol in man. Br J Clin Pharmacol. 1981;12:705–720. - PMC - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Elsevier Science full text link Elsevier Science Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp